BioSenic S.A. (FRA:BT1)

Market Cap	1.31M -23.1%
Revenue (ttm)	-2.39M -69.6%
Net Income	-4.00M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0020
Previous Close	0.0020
Day's Range	0.0020 - 0.0020
52-Week Range	0.0014 - 0.0032
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 7, 2026

About BioSenic

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Phase I clinical trial for veterinary use. BioSenic S.A. is headquartered in Saintes, Belgium.

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Jean-Luc Vandebroek
• Employees: 7
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BT1

Financial Performance

In 2024, BioSenic's revenue was 102,000, a decrease of -69.64% compared to the previous year's 336,000. Losses were -4.77 million, -83.43% less than in 2023.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error